Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug also fight gum disease?

NCT ID NCT07182123

Knowledge-focused Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study will test whether a weekly injection of a GLP-1 receptor agonist (a type 2 diabetes drug) can improve gum health in 30 adults who have both periodontitis and diabetes. Researchers will measure changes in gum pocket depth, bleeding, and tooth mobility. The goal is to gather enough data to plan a larger, more definitive trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (a diabetes drug that may also reduce gum inflammation)
What this could lead to
If it works, this could point toward a new way to treat gum disease using existing diabetes medications.
What could go wrong
This is a very small pilot study with only 30 people, not yet recruiting. It is designed to gather data for a future trial, not to prove effectiveness. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study participants will be recruited during routine care at the Clinical Division of Endocrinology and Diabetology, University Hospital Graz, where treatment is provided in accordance with current clinical guidelines. In line with the S2k guideline "Interrelationships between Periodontal Diseases and Diabetes Mellitus", patients receive standardized education on the bidirectional association between periodontitis and diabetes, as this relationship is regarded as clinically relevant. As part of recommended care, an annual periodontal examination is scheduled; accordingly, patients are referred from endocrinological diagnostics to the Clinical Division of Conservative Dentistry, Periodontology, and Prosthodontics for baseline periodontal assessment (Sanz, Ceriello et al. 2018).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent for participation and data protection * Diagnosis of type 2 diabetes * Diagnosis of chronic periodontitis (Caton, Armitage et al. 2018), presence of a PSI ≥ 3 in at least one sextant (Ainamo, Barmes et al. 1982) Exclusion Criteria: * Use of systemic antibiotics within the past 6 months * Systematic periodontal treatment within the past 24 months * Consumption of ≥ 5 cigarettes/day * Unstable cardiovascular disease * Chronic systemic diseases (e.g., rheumatoid arthritis, Crohn's disease, etc.) * Pregnancy * Use of the following medications: Immunosuppressants, Anticonvulsants, Calcium channel blockers * Drug or medication abuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic periodontitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic periodontitis diabetes mellitus periodontitis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes (DM) Periodontitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.